News Alimera Sciences, Inc.

Equities

ALIM

US0162592028

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-17 pm EDT			5-day change	1st Jan Change
3.55 ^USD	-0.84%		-5.33%	-17.82%

Mar. 25	Maxim Initiates Alimera Sciences at Buy Rating With $10 Price Target	MT
Mar. 19	Alimera Sciences, Inc. Announces First Patient Randomized in Radiation Retinopathy Trial Being Conducted by the DRCR Retina Network	CI

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Maxim Initiates Alimera Sciences at Buy Rating With $10 Price Target	Mar. 25	MT
Alimera Sciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	Mar. 20	AQ
Alimera Announces First Patient Randomized in Radiation Retinopathy Trial Being Conducted by the DRCR Retina Network	Mar. 19	AQ
Alimera Sciences, Inc. Announces First Patient Randomized in Radiation Retinopathy Trial Being Conducted by the DRCR Retina Network	Mar. 19	CI
Transcript : Alimera Sciences, Inc., Q4 2023 Earnings Call, Mar 07, 2024	Mar. 07
Alimera Sciences: Q4 Earnings Snapshot	Mar. 07	AQ
Alimera Sciences, Inc. Enters into the Seventh Amendment to Its Loan and Security Agreement	Mar. 07	CI
Earnings Flash (ALIM) ALIMERA SCIENCES Posts Q4 Revenue $26.3M	Mar. 07	MT
Earnings Flash (ALIM) ALIMERA SCIENCES Posts Q4 Revenue $26.3M	Mar. 07	MT
Alimera Sciences Reports Fourth Quarter and Full Year 2023 Results	Mar. 07	AQ
Alimera Sciences, Inc. Provides Revenue Guidance for the Year 2024	Mar. 07	CI
Alimera Sciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 07	CI
Alimera Sciences, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 07	CI
North American Morning Briefing : Powell Still in -2-	Mar. 07	DJ
Alimera Sciences to Report Fourth Quarter and Full Year 2023 Financial Results on March 7, 2024, and Provide Corporate Update	Feb. 29	AQ
The UK National Institute for Health and Care Excellence (NICE) Issues Final Draft Guidance to Provide Patients with a Natural Lens (Phakic Eye) Being Treated for Chronic Diabetic Macular Edema Access to ILUVIEN®	Feb. 08	AQ
Alimera Completes Recruitment for the Synchronicity Study	Jan. 04	CI
Alimera Completes Recruitment for the Synchronicity Study	Jan. 04	AQ
Alimera Sciences Appoints New CFO	Jan. 02	MT
Alimera Sciences, Inc. Names Elliot Maltz as Chief Financial Officer	Jan. 02	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Alimera Sciences, Inc.

Equities

ALIM

US0162592028

Summary

Filters